Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05p -2.08% 2.35p 2.30p 2.40p 2.40p 2.35p 2.40p 232,998 14:50:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.0 -2.0 -0.5 - 10.83

Nuformix Share Discussion Threads

Showing 101 to 124 of 125 messages
Chat Pages: 5  4  3  2  1
DateSubjectAuthorDiscuss
28/9/2018
13:36
And director buying
soupdragon55
28/9/2018
07:55
Good to see the company expanding the opportunities for NXP00228 September 2018Nuformix plc("Nuformix" or the "Company")Additional New NXP002 Patent FilingNuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs is pleased to announce a new patent filing in connection with its NXP002 fibrosis programme.Fibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Whilst, fibrosis treatments are in their infancy the emerging lung fibrosis market demonstrates their blockbuster potential. Markets for other fibrotic conditions are under-developed, with large and growing patient populations (e.g. the global liver disease market is predicted to reach $12.1 billion by 2022).Using cutting-edge human tissue disease models, Nuformix has previously demonstrated the potential for NXP002 to attenuate progression in established lung and liver fibrosis. This additional patent filing provides further strength and breadth to the existing NXP002 patent portfolio to best support further development and commercialisation for its NXP002 programme.Dr Dan Gooding, CEO, Nuformix plc, said: "NXP002 has demonstrated its broad anti-fibrotic potential with relevance to unmet needs in multiple life threatening conditions. Our additional patent filing strengthens Nuformix's ability to consider a wider range of options in the treatment of fibrosis. We hope to report shortly on the results of our extended study in idiopathic lung fibrosis using a highly innovative new human tissue model. Broadening and protecting the applications for NXP002 with this additional IP filing creates the potential to deliver wider benefit for patients whilst maximising value for investors."
soupdragon55
18/9/2018
13:49
Dr Dan Gooding, Chief Executive Officer of NuFormix (NFX) talks about the pre-clinical milestone for NXP001 being achieved, which triggers an initial £500,000 payment to the Company.(Interview starts at 8 minutes 20 seconds)Https://www.voxmarkets.co.uk/articles/prospex-oil-gas-nuformix-obtala-824b51b/
soupdragon55
16/9/2018
16:05
Nuformix CEO Dr. Dan Gooding said the news "basically means that the whole premise of Nuformix is validated"."When we've demonstrated human bioequivalence, this raises another £2m in milestone payments, which we'll be reinvesting into R&D and progressing our wider portfolio – the earlier stage assets in our portfolio are the key future value drivers for Nuformix."Demonstration of human bioequivalence is also the key to concluding further out-licensing deals for Rest of World rights to NXP001, again funds which we will redeploy using our de-risked development model to demonstrating how Nuformix's broader cocrystal technology portfolio can address unmet needs in conditions such as fibrosis, which I'm sure investors can identify as a sector of immense commercial value."
soupdragon55
14/9/2018
09:39
Smash'n'grab this morning, nice profit to start the day. Only a day trader here until they've gone through another round of fund raising, on my watch list.
rathean
14/9/2018
08:04
Good progress being made
soupdragon55
14/9/2018
07:12
RNS...out,the long awaited preclinical milestone achieved.good news
ashtree2
28/8/2018
16:53
RNS Today (28/08/18): "Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that it has agreed to amend the terms of the Convertible Loan Agreement ("Loan") dated 18th April 2017, extending the loan until 18th April 2019." Hang on a minute: the prospectus on the reverse into Levrett plc said at p75: "On 18 April 2017, the company announced that it had entered into a convertible loan note agreement for £200,000 with Mr Alan Miller, a private investor...Mr Miller has confirmed that, subject to the Company acquiring the entire issued share capital of Nuformix Limited, he will convert this loan into new ordinary shares in the company." So, Mr Miller changed his mind, did he? When? Why no RNS about this? Is this the same Alan Miller that is married to Gina Miller?
fred162
07/8/2018
11:51
Add eqt to that list
mertymcs
07/8/2018
11:43
Multibaggers for all! Where's Aberdeenman these days? He's gone v. quiet on this, COPL & RLH. Https://aberdeenman.com
bbmsionlypostafter
21/7/2018
11:55
Two 500K buys yesterday, last one At full ask 3.3p. Definite stake building Imho
john henry
12/7/2018
11:14
And still the 100K buying goes on. Something stirring here i think.
eyeofthetiger
12/7/2018
10:59
100K buyer still going....back over 4.20 from 29th June.
eyeofthetiger
12/7/2018
10:47
This one has had some very large block buys forming. I guess the bottom has been hit here. A nice move back over to highs and establish a good strong base.
eyeofthetiger
02/7/2018
16:11
100k buyer is now 100k seller. Hey ho. Guess they can't wait.
babbler
02/7/2018
08:32
Once the sheep have sold up should reflect the news
jon1962
02/7/2018
08:30
No one holds past news these days.. Ffs.
babbler
29/6/2018
10:14
Seems so. Big buys.
babbler
29/6/2018
08:39
Looks like seller has cleared with that 34m transfer.
soupdragon55
25/6/2018
07:57
Time to load IMO.
the_merlion
22/6/2018
16:33
in for a few myself today.
the_merlion
22/6/2018
15:21
Why not start with asking - Dear sir/madam, I am a shareholder of the company, please find a copy of my holdings. Can you tell me when the company will be updating the market and us shareholders. It is neither hard work or breaking the law to send a email. The time it took you to write that reply to me, you could have written an email and pressed send. Some PI's (nodding his head). Have a good weekend.
onceatraders
22/6/2018
15:11
errrmmm...ok then. Dear company, please can you tell us that price sensitive news will be released next week so I can buy in at a lower price today. Don't worry about insider trading laws.
soupdragon55
22/6/2018
14:42
Ask yourself - nuformix@gablecommunications.com DYOR.
onceatraders
Chat Pages: 5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20181016 02:01:33